Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Opportunities to Optimize Cancer Policies Panel Discussion

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




May
28
Today In Oncology
BPDCN FDA Approves Pivekimab Sunirine-pvzy
After the Founder: What a Cervical Cancer Program in Haiti Teaches About Sustaining Prevention
Off-the-Shelf CAR T-Cell Therapy Produces Deep, Durable Responses in Heavily Pretreated Multiple Myeloma
Sonrotoclax Receives Accelerated Approval in Relapsed or Refractory MCL
Early Breast Cancer Is Surgery Omission Possible Following Estrogen and Ablative Radiation Therapy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo